ThinPrep® Pap Test

A wealth of knowledge in a single vial1,2

The first liquid-based Pap test with FDA approval/clearance for sample collection of Pap, HPV, chlamydia/gonorrhea, and trichomoniasis testing from the same vial.

ThinPrep® Pap test:
FDA Approved
  • ThinPrep® Pap test
  • Aptima® HPV assay
  • Aptima® HPV 16 18/45
    genotype assay
  • cobas® HPV test
  • cobas® AMPLICOR CT/NG test
  • Hybrid Capture® 2 HPV test
FDA Cleared
  • Aptima Combo 2® assay
  • Aptima® Trichomonas
    vaginalis assay
  • ProbeTec® Chlamydia
    trachomatis (CT) test
  • ProbeTec® Neisseria
    gonorrhoeae (GC) test

The ThinPrep® Pap Test collection process provides:


Patient Comfort

Out-of-the-vial testing minimizes
the number of samples required
for multiple test results.


Clinician Versatility

Multiple FDA-approved ancillary
testing options available from a single vial.


Chain-of-Custody Verification

Closed-system lab processing limits opportunities for chain-of-custody errors.

Sample integrity and preservation

Collection device rinsed
in ThinPrep vial.

Full contents of vial preserved
for use in slide presentation.

Raising the bar in Pap testing results

Studies have reported reductions in unsatisfactory results when the ThinPrep® imaging system was implemented.3,4

The College of American Pathologists reported increased HSIL and LSIL categorization rates in labs that used the ThinPrep Pap test in 679 U.S. laboratories.5
  • Twice as much HSIL reported compared to SurePath.
  • SurePath – similar HSIL detection reported as conventional Pap testing.
HSIL Reporting Rate % (50th pctl) 5
HSIL Reporting Rate % (50th pctl) 5
Slides screened with the ThinPrep® Imaging system showed greater LSIL and HSIL categorization versus non-imaged slides
Independent Studies Show Increased LSIL and HSIL Cytology Categorization vs Manual ThinPrep Pap Test

This chart is a representation of clinical data from multiple published sources. The clinical studies represented within these sources were conducted using different study designs with various assays.

Refer to the ThinPrep Imaging System Instructions for Use for results of FDA approved studies.

UNSAT Rate 3
ASCUS Rate 3

A thorough approach to cervical cancer detection

While introduction of the Pap smear has steadily decreased squamous cell carcinoma, adenocarcinoma remains of great concern. Detecting adenocarcinoma should be an essential part of comprehensive cervical cancer screening.9
Histological Subtypes of Cervical Cancer 9,10

Addressing a dangerous threat

The ThinPrep® Pap test is the only Pap test with FDA-approved labeling citing multiple peer-reviewed publications supporting increased glandular disease detection compared to the conventional pap. 11-16

Sensitivity for cervical adenocarcinoma10

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?

1. ThinPrep 2000 System Operator’s Manual. MAN-02585-001, Rev. 008. Marlborough, MA: Hologic, Inc. 2021 2. Hologic, Inc. Data on File. 3. Miller, F., et al. Implementation of the ThinPrep Imaging System in a high-volume laboratory, Diagn Cytopathol. 2007;35(4):213-7. 4. Chivukula, M., et al. Introduction of the ThinPrep Imaging System (TIS): experience in a high volume academic practice. CytoJournal. 2007;4:6. doi:10.1186/1742-6413-4-6. 3. Data on File. Hologic, Inc. 5. Eversole GM, et al. Practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331-5. doi:10.1043/1543-2165-134.3.331. 6. Dziura B, et al. Performance of an imaging system vs. manual screening in the detection of squamous intra epithelial lesions of the uterine cervix. Acta Cytol. 2006;50(3):309-11. 7. Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol. 2007;104(1):134-8. 8. Klug SJ, Neis KJ, Harlfinger W, et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer. 2013;132(12):2849-2857. 9. Adegoke O, et al. Cervical Cancer Trends in the United States: A 35-Year Population-Based Analysis. J Women Health. 2012;21(10):1031-1037. 10. Islami et al. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med, 2019; 123: 316-323. 11. Schorge JO, et al. ThinPrep detection of cervical and a typical endocervical cells: a retrospective cohort study. Cancer Cytopathol. 2002;96:338-343. 12. Bai H, et al. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol. 2000;23:19-22. 13. Carpenter AB, et al. ThinPrep Pap Test: Performance biopsy follow-up in a university hospital. Cancer. 1999;87:105-112. 14. Guidos BJ, et al. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test. Diagn Cytopathol. 2000;23:260-265. 15. Ashfaq R, et al. ThinPrep Pap Test: Accuracy for glandular disease. Acta Cytol. 1999;43:81-85. 16. Wang N, et al. Histologic follow-up of atypical endocervical cells. Liquid based, thin-layer preparation vs. conventional pap smear. Acta Cytol. 2002;46:453-457.